honglian Yu

Prof. Dr. honglian Yu

orcid

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 April 2019 in Acta Biomaterialia
Verified
Journal Article
Closed access
ZZZhankui Zhao
Zhankui Zhao
DLDeqian Liu
Deqian Liu
YCYe Chen
Ye Chen
QKQingsheng Kong
Qingsheng Kong
DLDandan Li
Dandan Li
HYhonglian Yu
honglian Yu

28 June 2013 in Virus Genes
Verified
Journal Article
Closed access
PDF file
CLChunlan Liu
Chunlan Liu
YCYatang Chen
Yatang Chen
SLShan Li
Shan Li
HYhonglian Yu
honglian Yu
JZJie Zeng
Jie Zeng
FZFan Zhu
Fan Zhu

16 June 2023 in Discover Oncology
Verified
Journal Article
Open access
PDF file
QWQianqian Wang
Qianqian Wang
YSYing Shi
Ying Shi
QBQiang Bian
Qiang Bian
NZNaibin Zhang
Naibin Zhang
MWMeng Wang
Meng Wang
HYhonglian Yu
honglian Yu
Human endogenous retroviruses (HERVs) have evolved from exogenous retroviruses and account for approximately 8% of the human genome. A growing number of findings suggest that the abnormal expression of HERV genes is associated with schizophrenia, multiple sclerosis, endometriosis, breast cancer, bladder cancer and other diseases. HERV-W env (syncytin-1) is a membrane glycoprotein which plays an important role in placental development. It includes embryo implantation, fusion of syncytiotrophoblasts and of fertilized eggs, and immune response. The abnormal expression of syncytin-1 is related to placental development-related diseases such as preeclampsia, infertility, and intrauterine growth restriction, as well as tumors such as neuroblastoma, endometrial cancer, and endometriosis. This review mainly focused on the molecular interactions of syncytin-1 in placental development-related diseases and tumors, to explore whether syncytin-1 can be an emerging biological marker and potential therapeutic target.

1 November 2023 in Discover Oncology
Verified
Journal Article
Open access
PDF file
QBQiang Bian
Qiang Bian
BLBei Li
Bei Li
LZLuting Zhang
Luting Zhang
YSYinuo Sun
Yinuo Sun
ZZZhankui Zhao
Zhankui Zhao
HYhonglian Yu
honglian Yu
Prostate cancer is the second incidence of malignant tumors in men worldwide. Its incidence and mortality are increasing year by year. Enhanced expression of Cav1 in prostate cancer has been linked to both proliferation and metastasis of cancer cells, influencing disease progression. Dysregulation of the Cav1 gene shows a notable association with prostate cancer. Nevertheless, there is no systematic review to report about molecular signal mechanism of Cav1 and drug treatment in prostate cancer. This article reviews the structure, physiological and pathological functions of Cav1, the pathogenic signaling pathways involved in prostate cancer, and the current drug treatment of prostate cancer. Cav1 mainly affects the occurrence of prostate cancer through AKT/mTOR, H-RAS/PLCε, CD147/MMPs and other pathways, as well as substance metabolism including lipid metabolism and aerobic glycolysis. Baicalein, simvastatin, triptolide and other drugs can effectively inhibit the growth of prostate cancer. As a biomarker of prostate cancer, Cav1 may provide a potential therapeutic target for the treatment of prostate cancer.

1 January 2023 in Technology in Cancer Research & Treatment
Verified
Journal Article
Open access
NZNaibin Zhang
Naibin Zhang
QBQiang Bian
Qiang Bian
YGYankun Gao
Yankun Gao
QWQianqian Wang
Qianqian Wang
YSYing Shi
Ying Shi
HYhonglian Yu
honglian Yu
Human cancer statistics show that an increased incidence of urologic cancers such as bladder cancer, prostate cancer, and renal cell carcinoma. Due to the lack of early markers and effective therapeutic targets, their prognosis is poor. Fascin-1 is an actin-binding protein, which functions in the formation of cell protrusions by cross-linking with actin filaments. Studies have found that fascin-1 expression is elevated in most human cancers and is related to outcomes such as neoplasm metastasis, reduced survival, and increased aggressiveness. Fascin-1 has been considered as a potential therapeutic target for urologic cancers, but there is no comprehensive review to evaluate these studies. This review aimed to provide an enhanced literature review, outline, and summarize the mechanism of fascin-1 in urologic cancers and discuss the therapeutic potential of fascin-1 and the possibility of its use as a potential marker. We also focused on the correlation between the overexpression of fascin-1 and clinicopathological parameters. Mechanistically, fascin-1 is regulated by several regulators and signaling pathways (such as long noncoding RNA, microRNA, c-Jun N-terminal kinase, and extracellular regulated protein kinases). The overexpression of fascin-1 is related to clinicopathologic parameters such as pathological stage, bone or lymph node metastasis, and reduced disease-free survival. Several fascin-1 inhibitors (G2, NP-G2-044) have been evaluated in vitro and in preclinical models. The study proved the promising potential of fascin-1 as a newly developing biomarker and a potential therapeutic target that needs further investigation. The data also highlight the inadequacy of fascin-1 to serve as a novel biomarker for prostate cancer.

14 December 2017 in Scientific Reports
Verified
Journal Article
Open access
PDF file
ZZZhankui Zhao
Zhankui Zhao
HZHaizhou Zhu
Haizhou Zhu
HYhonglian Yu
honglian Yu
QKQingsheng Kong
Qingsheng Kong
CFChengjuan Fan
Chengjuan Fan
XDXiegang Ding
Xiegang Ding
In this meta-analysis study, we compared the oncological and functional outcomes of intrafascial radical prostatectomy (IFRP) with non-intrafascial radical prostatectomy (NIFRP) in the treatment of patients with low risk localized prostate cancer (PCa). Relevant articles were identified by searching PubMed, EMBASE, Cochrane Library, Ovid, and the ISI Web of Knowledge databases. A total of 2096 patients were included from 7 eligible studies. Results of the pooled data showed that the oncological outcomes including gleason score, positive surgical margin and biochemical free survival rates were similar between the two groups. IFRP was superior to NIFRP with lower postoperative complication rates (RR 0.57, 95% CI 0.38, 0.85, p = 0.006), higher continence rates at 3 months post-operation (RR: 1.14; 95% CI, 1.04, 1.26; p = 0.006), and higher potency rates at 6 months (RR: 1.53; 95% CI, 1.07, 2.18; p = 0.02) and 12 months post-operation (RR: 1.38; 95% CI, 1.11, 1.73; p = 0.005). Additionally, there was a tendency towards higher potency rate in patients ≤65 years old compared with patients >65 years old after IFRP. Overall, these findings suggest that IFRP in young patients with low risk localized PCa had less postoperative complications, shortened time to return to continence and improved potency rate without compromising complete tumor control.